Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/27/2003WO2003024442A2 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
03/27/2003WO2003024424A1 Stabilization of active agents by formulation into nanoparticulate form
03/27/2003WO2003024404A2 Chemokines as adjuvants of immune response
03/27/2003WO2003024402A2 Lpa receptor agonists and antagonists and methods of use
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024392A2 Compositions and methods for the diagnosis and treatment of tumor
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003024183A2 Wortmannin analogs and methods of using same
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2003000012A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
03/27/2003WO2002102311A3 Nanoparticles for treating targeted tissues and cells
03/27/2003WO2002098889A3 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
03/27/2003WO2002098356A3 Ppp2cs as modifiers of the p53 pathway and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003WO2002087496A3 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002078678A3 Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
03/27/2003WO2002078607A3 Mucin peptide with immunoenhancing properties
03/27/2003WO2002074237A3 Compositions and methods for the therapy and diagnosis of kidney cancer
03/27/2003WO2002059291A3 Biological organism for preparing pharmaceutical compositions for treating mammals
03/27/2003WO2002055100A3 Method and composition for inhibition of tumor growth and enhancing an immune response
03/27/2003WO2002053717A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002052019A3 22437, a human sulfatase and uses therefor
03/27/2003WO2002050023A3 Synthesis of pancrastistatin
03/27/2003WO2002047705A3 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use
03/27/2003WO2002034727A3 Treatment of gastrointestinal stromal tumors
03/27/2003WO2002034205B1 Using heat shock proteins to increase immune response
03/27/2003WO2002032413A3 A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
03/27/2003WO2002029060A3 Hematopoietin receptors hpr1 and hpr2
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002028381A3 Methods of inducing cancer cell death and tumor regression
03/27/2003WO2002026774A3 Melanocortin receptor ligands
03/27/2003WO2002026220A3 Taxoid conjugates as antimitotic and antitumor agents
03/27/2003WO2002022684A3 Transporters and ion channels
03/27/2003WO2002016419A9 Progression suppressed gene 13 (psgen 13) and uses thereof
03/27/2003WO2002013802A3 Method of treating estrogen receptor positive carcinoma
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002011667A3 Pharmaceutical compositions and methods useful for modulating angiogenesis
03/27/2003WO2002005857A3 Phosphatonin-related gene and methods of use thereof
03/27/2003WO2002000692A3 Pd-l2 molecules: pd-1 ligands and uses therefor
03/27/2003WO2001092218A3 Polyamine analogues as therapeutic and diagnostic agents
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060638 C7 carbamate substituted taxanes
03/27/2003US20030060635 Methods of using bis-indolylquinones
03/27/2003US20030060629 Pyrazine derivatives as modulators of tyrosine kinases
03/27/2003US20030060624 Reacting 2-chloro-4- trifluoromethyl-phenyl)-acetonitrile in the presence of a palladium catalyst and a base to form indene derivative
03/27/2003US20030060623 Having microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tunior cells or other hyperproliferative cellular disease
03/27/2003US20030060621 Preparation of indolopyrrolocarbazole derivative; obtain chemical intermediates, deblock and recover indolopyrrolocarbazole derivative
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060613 Protein for use in the treatment of bone, tumor and inflammatory disorders
03/27/2003US20030060491 Bicyclic aromatic compounds
03/27/2003US20030060487 Useful for treatments for peptide aggregation associated with disease state such as Alzhemimer's diseases
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060450 Such as 4-(3-chlorophenyl)-6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl) -methyl)-1-methyl-2(1H)quinoline for treating mammalian tumors via inhibiting farnesyl transferase
03/27/2003US20030060442 Immunostimulatory cyktokines include interleukins as antitumor agents, dervived from dendritic cells modified via viral vector transduction/centrifugation
03/27/2003US20030060433 Reducing the severity of cancer
03/27/2003US20030060432 Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers
03/27/2003US20030060429 Stilbene derivatives and taxanes, vinca alkaloids, alkylating agents, antimetabolites, epidophylloptoxins, platinum compounds, and antibiotics; antitumor agents
03/27/2003US20030060427 Dissolving an organic compound having a lactone nucleus in lower alcohol and water; antitumor agents
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030059943 Inhibition of gene expression in preferential cell; obtain cells, infect with viral particles, recover infected cells, express viral sequences, monitor adjustment in gene expression
03/27/2003US20030059937 Antibodies that immunospecifically bind BLyS
03/27/2003US20030059922 Sphingosine1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059890 Protein for use as antiinflammatory, antiproliferative and antipyretic agents
03/27/2003US20030059871 Hematopoietin receptors HPR1 and HPR2
03/27/2003US20030059868 Retinal cell lines with extended life-span and their applications
03/27/2003US20030059863 N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059856 Detection of modulator of receptor binding activity; obtain sample containing receptor, incubate with test agent and ligand, monitor binding activity of ligand, adjusment in binding activity indicates modulator
03/27/2003US20030059852 Detecting modulators of integrin activity; obtain sample containing integrin, incubate with test compound, monitor adjustment in integrin activity, adjustment in integrin activity indicates modulator
03/27/2003US20030059812 HDAC9 polypeptides and polynucleotides and uses thereof
03/27/2003US20030059796 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis
03/27/2003US20030059767 Zinc finger protein derivatives and methods therefor
03/27/2003US20030059470 Dispersions for the formulation of slightly or poorly soluble agents
03/27/2003US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor
03/27/2003US20030059427 Isolation and characterization of highly active anti-CD40 antibody
03/27/2003US20030059417 Methods and compositions for diagnosing and treating disorders involving angiogenesis
03/27/2003US20030059414 Cell populations which co-express CD49c and CD90
03/27/2003US20030059375 Method for treating lung cancers
03/27/2003CA2709442A1 Cell populations which co-express cd49c and cd90
03/27/2003CA2708349A1 Compositions and methods for the diagnosis and treatment of tumor
03/27/2003CA2492826A1 Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
03/27/2003CA2492823A1 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
03/27/2003CA2466243A1 Indolizines as kinase protein inhibitors
03/27/2003CA2465978A1 Inhibitors of histone deacetylase
03/27/2003CA2461074A1 Methods and compositions of novel triazine compounds
03/27/2003CA2460942A1 Substituted pyrazolyl compounds for the treatment of inflammation
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460719A1 Igf-binding protein-derived peptide or small molecule
03/27/2003CA2460713A1 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
03/27/2003CA2460620A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents
03/27/2003CA2460587A1 Anti-pdgf antibodies and methods for producing engineered antibodies
03/27/2003CA2460544A1 Anti-inflammatory agent
1 ... 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 ... 2211